Ann: Security Class Reinstatement to Quotation- OPTOB, page-490

If you have a background or interest in STEM, OPT could be a fascinating stock to study, in my opinion. We're dealing with a binary outcome here. On the one hand, we have the P2b trial results (n=366), which provide a solid statical foundation, combined with the P3 protocol (n=990+), and the exclusion of poor-outcome groups (RAP).

On the other hand, success hinges on achieving a statistically significant result for a 4-letter gain or more, which would signal a strong hit. Conversely, there’s the risk of sub-3-letter results or an unexpectedly poor outcome.

We also know how the market values drug companies as a multiple of sales and that OPT-302’s commercial production method is already established. Given these factors, the first step should be to thoroughly review and quantify the risk of P3 failure and the subsequent likelihood of obtaining a biologics license. This includes considering timelines and potential regulatory hurdles. IMHO the upside will take care of itself—your focus should be on assessing and managing downside risks.

Note for many of us on HotCopper, we’re at stages in our lives where our families are raised, mortgages are paid off, and we’ve built financial security through property investments, superannuation, etc. This gives us the flexibility to take on greater risks, knowing that even a significant loss wouldn’t drastically impact our lifestyles—whether that’s the difference between a Model Y or a Lexus, holidays in Thailand versus Switzerland, or helping our kids with the Bank of Mum and Dad instead telling them to phone Westpac.

My honest advice is to consider strategies to minimize your tax liabilities and optimize your savings. Not saying you are , but don't risk your future by going all in—there are no guarantees here, and 100% certainty is never on the table. Hypothetically if you purchased after researching, OPTOB with money you are 100% OK to lose completely then go for it.